Benzinga··Tanya RawatORIC Pharmaceuticals Crashes 25% After Hours Despite Positive Trial Data
ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.
ORICstock volatilitybiotech